Table 7.
Response at any time according to the involved organs after ruxolitinib treatment.
| Subgroup | ORR | CRR | ||
|---|---|---|---|---|
| Cumulative incidence (%) | 95%CI | Cumulative incidence (%) | 95%CI | |
| SR-aGVHD | ||||
| Skin | 78.3 | 63.2–93.3 | 68.6 | 37.2–99.9 |
| Gut | 78.9 | 66.6–91.2 | 57.9 | 37.8–78.1 |
| Liver | 60.4 | 37.2–83.5 | 49.1 | 32.8–65.5 |
| SR-cGVHD | ||||
| Skin | 73.2 | 58.7–87.7 | 30.1 | 18.2–42.0 |
| Gut | 69.2 | 50.9–87.5 | 25.7 | 2.4–48.9 |
| Liver | 65.7 | 45.0–86.3 | 32.7 | 15.8–49.6 |
| Mouth | 76.5 | 61.5–91.5 | 34.0 | 24.7–43.3 |
| Eyes | 61.1 | 38.7–83.5 | 16.7 | 2.4–31.0 |
| Lung | 47.3 | 29.8–64.9 | 11.1 | 1.2–21.0 |
| Joints and fascia | 67.4 | 46.4–88.3 | 11.9 | 0.0–23.8 |
| Esophagus | 50.0 | NA | 0.0 | NA |
CI, confidence interval; CRR, complete response rate; NA, not available; ORR, overall response rate; SR-aGVHD, steroid-refractory acute graft-versus-host disease; SR-cGVHD, steroid-refractory chronic graft-versus-host disease.